(SSNC) SS&C Technologies Holdings - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US78467J1007
Stock: Financial Software, Healthcare Software, Fund Administration, Outsourcing
Total Rating 40
Risk 78
Buy Signal 0.23
| Risk 5d forecast | |
|---|---|
| Volatility | 24.1% |
| Relative Tail Risk | -5.22% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.39 |
| Alpha | -30.18 |
| Character TTM | |
|---|---|
| Beta | 0.851 |
| Beta Downside | 1.111 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.56% |
| CAGR/Max DD | 0.55 |
EPS (Earnings per Share)
Revenue
Description: SSNC SS&C Technologies Holdings March 05, 2026
SS&C Technologies Holdings, Inc. (SSNC) provides software and software-enabled services to the financial services and healthcare sectors. The companys offerings span the entire investment lifecycle, from front-office trading and modeling to middle-office portfolio management and back-office accounting and compliance.
In financial services, SSNCs technology stack supports securities accounting, trading, and various operational functions. This includes reconciliation, performance measurement, and regulatory reporting. The financial technology sector is characterized by a strong demand for integrated solutions that streamline complex processes and ensure regulatory compliance.
For the healthcare industry, SSNC offers solutions for claims adjudication, benefit management, and care management. These services are critical for efficient healthcare administration. The healthcare technology market is driven by the need for cost reduction, improved patient outcomes, and data-driven insights.
SSNC also provides professional services, including consulting, implementation, and ongoing support for its software products. The company operates globally, with a presence across North America, Europe, Asia Pacific, and other regions. Further research on ValueRay can provide detailed financial metrics and competitive analysis.
Headlines to watch out for
- Financial services industry spending impacts software and service demand
- Healthcare industry IT budgets drive solution adoption
- Acquisition strategy fuels revenue growth and market share
- Regulatory changes create demand for compliance software
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 796.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 1.25 > 1.0 |
| NWC/Revenue: 6.00% < 20% (prev 8.64%; Δ -2.64% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.76b > Net Income 796.9m |
| Net Debt (4.07b) to EBITDA (2.10b): 1.93 < 3 |
| Current Ratio: 1.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (251.5m) vs 12m ago -0.91% < -2% |
| Gross Margin: 48.17% > 18% (prev 0.49%; Δ 4.77k% > 0.5%) |
| Asset Turnover: 31.55% > 50% (prev 30.89%; Δ 0.67% > 0%) |
| Interest Coverage Ratio: 3.29 > 6 (EBITDA TTM 2.10b / Interest Expense TTM 426.3m) |
Altman Z'' 1.55
| A: 0.02 (Total Current Assets 5.49b - Total Current Liabilities 5.11b) / Total Assets 20.71b |
| B: 0.20 (Retained Earnings 4.18b / Total Assets 20.71b) |
| C: 0.07 (EBIT TTM 1.40b / Avg Total Assets 19.88b) |
| D: 0.28 (Book Value of Equity 3.89b / Total Liabilities 13.77b) |
| Altman-Z'' Score: 1.55 = BB |
Beneish M -3.52
| DSRI: 0.39 (Receivables 1.72b/4.11b, Revenue 6.27b/5.88b) |
| GMI: 1.01 (GM 48.17% / 48.68%) |
| AQI: 0.99 (AQ_t 0.71 / AQ_t-1 0.72) |
| SGI: 1.07 (Revenue 6.27b / 5.88b) |
| TATA: -0.05 (NI 796.9m - CFO 1.76b) / TA 20.71b) |
| Beneish M-Score: -3.52 (Cap -4..+1) = AAA |
What is the price of SSNC shares?
As of March 14, 2026, the stock is trading at USD 72.98 with a total of 2,380,832 shares traded.
Over the past week, the price has changed by -5.24%, over one month by -0.02%, over three months by -16.67% and over the past year by -9.01%.
Over the past week, the price has changed by -5.24%, over one month by -0.02%, over three months by -16.67% and over the past year by -9.01%.
Is SSNC a buy, sell or hold?
SS&C Technologies Holdings has received a consensus analysts rating of 4.33.
Therefore, it is recommended to buy SSNC.
- StrongBuy: 6
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SSNC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 99 | 35.7% |
| Analysts Target Price | 99 | 35.7% |
SSNC Fundamental Data Overview March 10, 2026
P/E Trailing = 24.0603
P/E Forward = 11.325
P/S = 2.951
P/B = 2.6852
P/EG = 0.7978
Revenue TTM = 6.27b USD
EBIT TTM = 1.40b USD
EBITDA TTM = 2.10b USD
Long Term Debt = 7.41b USD (from longTermDebt, last quarter)
Short Term Debt = 25.0m USD (from shortTermDebt, last quarter)
Debt = 7.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.07b USD (from netDebt column, last quarter)
Enterprise Value = 22.58b USD (18.51b + Debt 7.65b - CCE 3.57b)
Interest Coverage Ratio = 3.29 (Ebit TTM 1.40b / Interest Expense TTM 426.3m)
EV/FCF = 13.48x (Enterprise Value 22.58b / FCF TTM 1.68b)
FCF Yield = 7.42% (FCF TTM 1.68b / Enterprise Value 22.58b)
FCF Margin = 26.71% (FCF TTM 1.68b / Revenue TTM 6.27b)
Net Margin = 12.71% (Net Income TTM 796.9m / Revenue TTM 6.27b)
Gross Margin = 48.17% ((Revenue TTM 6.27b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 47.77% (prev 47.69%)
Tobins Q-Ratio = 1.09 (Enterprise Value 22.58b / Total Assets 20.71b)
Interest Expense / Debt = 1.46% (Interest Expense 111.4m / Debt 7.65b)
Taxrate = 11.86% (26.1m / 220.1m)
NOPAT = 1.23b (EBIT 1.40b * (1 - 11.86%))
Current Ratio = 1.07 (Total Current Assets 5.49b / Total Current Liabilities 5.11b)
Debt / Equity = 1.11 (Debt 7.65b / totalStockholderEquity, last quarter 6.89b)
Debt / EBITDA = 1.93 (Net Debt 4.07b / EBITDA 2.10b)
Debt / FCF = 2.43 (Net Debt 4.07b / FCF TTM 1.68b)
Total Stockholder Equity = 6.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.01% (Net Income 796.9m / Total Assets 20.71b)
RoE = 11.57% (Net Income TTM 796.9m / Total Stockholder Equity 6.88b)
RoCE = 9.80% (EBIT 1.40b / Capital Employed (Equity 6.88b + L.T.Debt 7.41b))
RoIC = 8.94% (NOPAT 1.23b / Invested Capital 13.81b)
WACC = 6.78% (E(18.51b)/V(26.16b) * Re(9.05%) + D(7.65b)/V(26.16b) * Rd(1.46%) * (1-Tc(0.12)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.12%
[DCF] Terminal Value 83.32% ; FCFF base≈1.53b ; Y1≈1.60b ; Y5≈1.86b
[DCF] Fair Price = 158.1 (EV 42.66b - Net Debt 4.07b = Equity 38.59b / Shares 244.0m; r=6.78% [WACC]; 5y FCF grow 5.19% → 2.90% )
EPS Correlation: 15.67 | EPS CAGR: 8.37% | SUE: 0.95 | # QB: 2
Revenue Correlation: 97.94 | Revenue CAGR: 6.73% | SUE: 2.67 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.66 | Chg7d=+0.039 | Chg30d=+0.032 | Revisions Net=+3 | Analysts=9
EPS current Year (2026-12-31): EPS=6.80 | Chg7d=-0.047 | Chg30d=+0.190 | Revisions Net=+8 | Growth EPS=+10.7% | Growth Revenue=+7.0%
EPS next Year (2027-12-31): EPS=7.22 | Chg7d=-0.216 | Chg30d=+0.058 | Revisions Net=+0 | Growth EPS=+6.3% | Growth Revenue=+4.9%
[Analyst] Revisions Ratio: +0.60 (4 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 9.1% - Earnings Yield 4.2%)
[Growth] Growth Spread = +2.5% (Analyst 7.4% - Implied 4.9%)
P/E Forward = 11.325
P/S = 2.951
P/B = 2.6852
P/EG = 0.7978
Revenue TTM = 6.27b USD
EBIT TTM = 1.40b USD
EBITDA TTM = 2.10b USD
Long Term Debt = 7.41b USD (from longTermDebt, last quarter)
Short Term Debt = 25.0m USD (from shortTermDebt, last quarter)
Debt = 7.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.07b USD (from netDebt column, last quarter)
Enterprise Value = 22.58b USD (18.51b + Debt 7.65b - CCE 3.57b)
Interest Coverage Ratio = 3.29 (Ebit TTM 1.40b / Interest Expense TTM 426.3m)
EV/FCF = 13.48x (Enterprise Value 22.58b / FCF TTM 1.68b)
FCF Yield = 7.42% (FCF TTM 1.68b / Enterprise Value 22.58b)
FCF Margin = 26.71% (FCF TTM 1.68b / Revenue TTM 6.27b)
Net Margin = 12.71% (Net Income TTM 796.9m / Revenue TTM 6.27b)
Gross Margin = 48.17% ((Revenue TTM 6.27b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 47.77% (prev 47.69%)
Tobins Q-Ratio = 1.09 (Enterprise Value 22.58b / Total Assets 20.71b)
Interest Expense / Debt = 1.46% (Interest Expense 111.4m / Debt 7.65b)
Taxrate = 11.86% (26.1m / 220.1m)
NOPAT = 1.23b (EBIT 1.40b * (1 - 11.86%))
Current Ratio = 1.07 (Total Current Assets 5.49b / Total Current Liabilities 5.11b)
Debt / Equity = 1.11 (Debt 7.65b / totalStockholderEquity, last quarter 6.89b)
Debt / EBITDA = 1.93 (Net Debt 4.07b / EBITDA 2.10b)
Debt / FCF = 2.43 (Net Debt 4.07b / FCF TTM 1.68b)
Total Stockholder Equity = 6.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.01% (Net Income 796.9m / Total Assets 20.71b)
RoE = 11.57% (Net Income TTM 796.9m / Total Stockholder Equity 6.88b)
RoCE = 9.80% (EBIT 1.40b / Capital Employed (Equity 6.88b + L.T.Debt 7.41b))
RoIC = 8.94% (NOPAT 1.23b / Invested Capital 13.81b)
WACC = 6.78% (E(18.51b)/V(26.16b) * Re(9.05%) + D(7.65b)/V(26.16b) * Rd(1.46%) * (1-Tc(0.12)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.12%
[DCF] Terminal Value 83.32% ; FCFF base≈1.53b ; Y1≈1.60b ; Y5≈1.86b
[DCF] Fair Price = 158.1 (EV 42.66b - Net Debt 4.07b = Equity 38.59b / Shares 244.0m; r=6.78% [WACC]; 5y FCF grow 5.19% → 2.90% )
EPS Correlation: 15.67 | EPS CAGR: 8.37% | SUE: 0.95 | # QB: 2
Revenue Correlation: 97.94 | Revenue CAGR: 6.73% | SUE: 2.67 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.66 | Chg7d=+0.039 | Chg30d=+0.032 | Revisions Net=+3 | Analysts=9
EPS current Year (2026-12-31): EPS=6.80 | Chg7d=-0.047 | Chg30d=+0.190 | Revisions Net=+8 | Growth EPS=+10.7% | Growth Revenue=+7.0%
EPS next Year (2027-12-31): EPS=7.22 | Chg7d=-0.216 | Chg30d=+0.058 | Revisions Net=+0 | Growth EPS=+6.3% | Growth Revenue=+4.9%
[Analyst] Revisions Ratio: +0.60 (4 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 9.1% - Earnings Yield 4.2%)
[Growth] Growth Spread = +2.5% (Analyst 7.4% - Implied 4.9%)